Evotec SE

1EVT

Company Profile

  • Business description

    Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

  • Contact

    Essener Bogen 7
    Manfred Eigen Campus
    Hamburg22419
    DEU

    T: +49 40560810

    E: [email protected]

    https://www.evotec.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    4,766

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,753.304.60-0.05%
CAC 407,656.1227.61-0.36%
DAX 4023,317.81116.84-0.50%
Dow JONES (US)42,171.6644.14-0.10%
FTSE 1008,843.479.440.11%
HKSE23,231.48479.21-2.02%
NASDAQ19,546.2725.180.13%
Nikkei 22538,579.80305.35-0.79%
NZX 50 Index12,582.4944.83-0.36%
S&P 5005,980.871.85-0.03%
S&P/ASX 2008,535.904.700.06%
SSE Composite Index3,359.7829.03-0.86%

Market Movers